Trial Watch—Oncolytic viruses and cancer therapy

OncoImmunology

Volumn 5, Issue 2, 2016, Pages

  Pol, Jonathan ^a,b,c,d,e   Buqué, Aitziber ^a,b,c,d,e   Aranda, Fernando ^f   Bloy, Norma ^a,b,c,d,e   Cremer, Isabelle ^a,b,c,d   Eggermont, Alexander ^e   Erbs, Philippe ^g   Fucikova, Jitka ^h,i   Galon, Jérôme ^a,b,c,d   Limacher, Jean Marc ^g   Preville, Xavier ^g   Sautès Fridman, Catherine ^a,b,c,d   Spisek, Radek ^h,i   Zitvogel, Laurence ^a,e   Kroemer, Guido ^{a,b,c,d,e,j,k}   Galluzzi, Lorenzo ^a,b,c,d,e  

^a INSERM   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c SORBONNE UNIVERSITÉ   (France)

^d CENTRE DE RECHERCHE DES CORDELIERS   (France)

^e INSTITUT GUSTAVE ROUSSY   (France)

^f INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^g TRANSGENE S A   (France)

^h Sotio   (Czech Republic)

ⁱ UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

^j HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^k KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

more..

Author keywords

Cavatak ; GM CSF; JX 594; ONCOS 102; Reolysin ; talimogene laherparepvec

Indexed keywords

EID: 84959440182     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2015.1117740     Document Type: Article

References (271)

1. S.J.Russell, K.W.Peng, J.C.Bell. Oncolytic virotherapy. Nat Biotechnol 2012; 30:658-70; PMID:22781695; http://dx.doi.org/10.1038/nbt.2287
2. M.J.Vaha-Koskela, J.E.Heikkila, A.E.Hinkkanen. Oncolytic viruses in cancer therapy. Cancer Lett 2007; 254:178-216; PMID:17383089; http://dx.doi.org/10.1016/j.canlet.2007.02.002
3. W.Walther, P.M.Schlag. Current status of gene therapy for cancer. Curr Opin Oncol 2013; 25:659-64; PMID:24100345; http://dx.doi.org/10.1097/CCO.0000000000000004
4. J.Bell, G.McFadden. Viruses for tumor therapy. Cell Host Microbe 2014; 15:260-5; PMID:24629333; http://dx.doi.org/10.1016/j.chom.2014.01.002
5. B.D.Lichty, C.J.Breitbach, D.F.Stojdl, J.C.Bell. Going viral with cancer immunotherapy. Nat Rev Cancer 2014; 14:559-67; PMID:24990523; http://dx.doi.org/10.1038/nrc3770
6. T.A.Cheema, P.E.Fecci, J.Ning, S.D.Rabkin. Immunovirotherapy for the treatment of glioblastoma. Oncoimmunology 2014; 3:e27218; PMID:24575383; http://dx.doi.org/10.4161/onci.27218
7. T.S.Griffith, M.Kawakita, J.Tian, J.Ritchey, J.Tartaglia, I.Sehgal, T.C.Thompson, W.Zhao, T.L.Ratliff. Inhibition of murine prostate tumor growth and activation of immunoregulatory cells with recombinant canarypox viruses. J Natl Cancer Inst 2001; 93:998-1007; PMID:11438565; http://dx.doi.org/10.1093/jnci/93.13.998
8. A.R.Makela, H.Matilainen, D.J.White, E.Ruoslahti, C.Oker-Blom. Enhanced baculovirus-mediated transduction of human cancer cells by tumor-homing peptides. J Virol 2006; 80:6603-11; PMID:16775347; http://dx.doi.org/10.1128/JVI.00528-06
9. P.Singh, G.Destito, A.Schneemann, M.Manchester. Canine parvovirus-like particles, a novel nanomaterial for tumor targeting. J Nanobiotechnology 2006; 4:2; PMID:16476163; http://dx.doi.org/10.1186/1477-3155-4-2
10. L.Galluzzi, C.Brenner, E.Morselli, Z.Touat, G.Kroemer. Viral control of mitochondrial apoptosis. PLoS Pathog 2008; 4:e1000018; PMID:18516228; http://dx.doi.org/10.1371/journal.ppat.1000018
11. N.Boisgerault, J.B.Guillerme, D.Pouliquen, M.Mesel-Lemoine, C.Achard, C.Combredet, J.F.Fonteneau, F.Tangy, M.Grégoire. Natural oncolytic activity of live-attenuated measles virus against human lung and colorectal adenocarcinomas. Biomed Res Int 2013; 2013:387362; PMID:23586034; http://dx.doi.org/10.1155/2013/387362
12. O.Donnelly, K.Harrington, A.Melcher, H.Pandha. Live viruses to treat cancer. J R Soc Med 2013; 106:310-4; PMID:23824333; http://dx.doi.org/10.1177/0141076813494196
13. G.Kochneva, E.Zonov, A.Grazhdantseva, A.Yunusova, G.Sibolobova, E.Popov, O.Taranov, S.Netesov, P.Chumakov, E.Ryabchikova. Apoptin enhances the oncolytic properties of vaccinia virus and modifies mechanisms of tumor regression. Oncotarget 2014; 5:11269-82; PMID:25358248; http://dx.doi.org/10.18632/oncotarget.2579
14. M.K.Kim, C.J.Breitbach, A.Moon, J.Heo, Y.K.Lee, M.Cho, J.W.Lee, S.G.Kim, D.H.Kang, J.C.Bell et al. Oncolytic and immunotherapeutic vaccinia induces antibody-mediated complement-dependent cancer cell lysis in humans. Sci Transl Med 2013; 5:185ra63; PMID:23677592; http://dx.doi.org/10.1186/1479-5876-11-185
15. I.Liikanen, L.Ahtiainen, M.L.Hirvinen, S.Bramante, V.Cerullo, P.Nokisalmi, O.Hemminki, I.Diaconu, S.Pesonen, A.Koski et al. Oncolytic adenovirus with temozolomide induces autophagy and antitumor immune responses in cancer patients. Mol Ther 2013; 21:1212-23; PMID:23546299; http://dx.doi.org/10.1038/mt.2013.51
16. A.Kanerva, P.Nokisalmi, I.Diaconu, A.Koski, V.Cerullo, I.Liikanen, S.Tähtinen, M.Oksanen, R.Heiskanen, S.Pesonen et al. Antiviral and antitumor T-cell immunity in patients treated with GM-CSF-coding oncolytic adenovirus. Clin Cancer Res 2013; 19:2734-44; PMID:23493351; http://dx.doi.org/10.1158/1078-0432.CCR-12-2546
17. C.Batenchuk, F.Le Boeuf, L.Stubbert, T.Falls, H.L.Atkins, J.C.Bell, D.P.Conrad. Non-replicating rhabdovirus-derived particles (NRRPs) eradicate acute leukemia by direct cytolysis and induction of antitumor immunity. Blood Cancer J 2013; 3:e123; PMID:23852158; http://dx.doi.org/10.1038/bcj.2013.23
18. A.Kleijn, J.Kloezeman, E.Treffers-Westerlaken, G.Fulci, S.Leenstra, C.Dirven, R.Debets, M.Lamfers. The in vivo therapeutic efficacy of the oncolytic adenovirus Delta24-RGD is mediated by tumor-specific immunity. PLoS One 2014; 9:e97495; PMID:24866126; http://dx.doi.org/10.1371/journal.pone.0097495
19. H.Jiang, J.Fueyo. Healing after death: antitumor immunity induced by oncolytic adenoviral therapy. Oncoimmunology 2014; 3:e947872; PMID:25954598; http://dx.doi.org/10.4161/21624011.2014.947872
20. D.Grote, S.J.Russell, T.I.Cornu, R.Cattaneo, R.Vile, G.A.Poland, A.K.Fielding. Live attenuated measles virus induces regression of human lymphoma xenografts in immunodeficient mice. Blood 2001; 97:3746-54; PMID:11389012; http://dx.doi.org/10.1182/blood.V97.12.3746
21. K.W.Peng, C.J.TenEyck, E.Galanis, K.R.Kalli, L.C.Hartmann, S.J.Russell. Intraperitoneal therapy of ovarian cancer using an engineered measles virus. Cancer Res 2002; 62:4656-62; PMID:12183422
22. A.Kanerva, K.R.Zinn, K.W.Peng, T.Ranki, L.Kangasniemi, T.R.Chaudhuri, R.A.Desmond, M.Wang, K.Takayama, T.Hakkarainen et al. Noninvasive dual modality in vivo monitoring of the persistence and potency of a tumor targeted conditionally replicating adenovirus. Gene Ther 2005; 12:87-94; PMID:15385953; http://dx.doi.org/10.1038/sj.gt.3302387
23. K.D.Fisher, Y.Stallwood, N.K.Green, K.Ulbrich, V.Mautner, L.W.Seymour. Polymer-coated adenovirus permits efficient retargeting and evades neutralising antibodies. Gene Ther 2001; 8:341-8; PMID:11313809; http://dx.doi.org/10.1038/sj.gt.3301389
24. I.Massari, A.Donnini, K.Argentati, S.Straino, A.Mangoni, C.Gaetano, C.Viticchi, M.Capogrossi, M.Provinciali. Age-dependent effects of repeated immunization with a first generation adenovirus vector on the immune response and transgene expression in young and old rats. Exp Gerontol 2002; 37:823-31; PMID:12175482; http://dx.doi.org/10.1016/S0531-5565(02)00011-6
25. K.Ikeda, H.Wakimoto, T.Ichikawa, S.Jhung, F.H.Hochberg, D.N.Louis, E.A.Chiocca. Complement depletion facilitates the infection of multiple brain tumors by an intravascular, replication-conditional herpes simplex virus mutant. J Virol 2000; 74:4765-75; PMID:10775615; http://dx.doi.org/10.1128/JVI.74.10.4765-4775.2000
26. M.N.Pensiero, C.A.Wysocki, K.Nader, G.E.Kikuchi. Development of amphotropic murine retrovirus vectors resistant to inactivation by human serum. Hum Gene Ther 1996; 7:1095-101; PMID:8773511; http://dx.doi.org/10.1089/hum.1996.7.9-1095
27. K.M.Bernt, S.Ni, A.Gaggar, Z.Y.Li, D.M.Shayakhmetov, A.Lieber. The effect of sequestration by nontarget tissues on anti-tumor efficacy of systemically applied, conditionally replicating adenovirus vectors. Mol Ther 2003; 8:746-55; PMID:14599807; http://dx.doi.org/10.1016/j.ymthe.2003.07.006
28. D.M.Underhill, A.Ozinsky. Phagocytosis of microbes: complexity in action. Annu Rev Immunol 2002; 20:825-52; PMID:11861619; http://dx.doi.org/10.1146/annurev.immunol.20.103001.114744
29. K.Taipale, I.Liikanen, J.Juhila, R.Turkki, S.Tahtinen, M.Kankainen, L.Vassilev, A.Ristimäki, A.Koski, A.Kanerva et al. Chronic activation of innate immunity correlates with poor prognosis in cancer patients treated with oncolytic adenovirus. Mol Ther 2015; PMID:26310629; http://dx.doi.org/10.1038/mt.2015.143
30. C.A.Alvarez-Breckenridge, J.Yu, M.A.Caligiuri, E.A.Chiocca. Uncovering a novel mechanism whereby NK cells interfere with glioblastoma virotherapy. Oncoimmunology 2013; 2:e23658; PMID:23734319; http://dx.doi.org/10.4161/onci.23658
31. C.Ayala-Breton, G.N.Barber, S.J.Russell, K.W.Peng. Retargeting vesicular stomatitis virus using measles virus envelope glycoproteins. Hum Gene Ther 2012; 23:484-91; PMID:22171635; http://dx.doi.org/10.1089/hum.2011.146
32. A.Muik, I.Kneiske, M.Werbizki, D.Wilflingseder, T.Giroglou, O.Ebert, A.Kraft, U.Dietrich, G.Zimmer, S.Momma et al. Pseudotyping vesicular stomatitis virus with lymphocytic choriomeningitis virus glycoproteins enhances infectivity for glioma cells and minimizes neurotropism. J Virol 2011; 85:5679-84; PMID:21450833; http://dx.doi.org/10.1128/JVI.02511-10
33. H.Uchida, M.Marzulli, K.Nakano, W.F.Goins, J.Chan, C.S.Hong, L.Mazzacurati, J.Y.Yoo, A.Haseley, H.Nakashima et al. Effective treatment of an orthotopic xenograft model of human glioblastoma using an EGFR-retargeted oncolytic herpes simplex virus. Mol Ther 2013; 21:561-9; PMID:23070115; http://dx.doi.org/10.1038/mt.2012.211
34. P.Bach, T.Abel, C.Hoffmann, Z.Gal, G.Braun, I.Voelker, C.R.Ball, I.C.Johnston, U.M.Lauer, C.Herold-Mende et al. Specific elimination of CD133+ tumor cells with targeted oncolytic measles virus. Cancer Res 2013; 73:865-74; PMID:23293278; http://dx.doi.org/10.1158/0008-5472.CAN-12-2221
35. P.Nanni, V.Gatta, L.Menotti, C.De Giovanni, M.Ianzano, A.Palladini, V.Grosso, M.Dall'ora, S.Croci, G.Nicoletti et al. Preclinical therapy of disseminated HER-2(+) ovarian and breast carcinomas with a HER-2-retargeted oncolytic herpesvirus. PLoS Pathog 2013; 9:e1003155; PMID:23382683; http://dx.doi.org/10.1371/journal.ppat.1003155
36. K.Sugio, F.Sakurai, K.Katayama, K.Tashiro, H.Matsui, K.Kawabata, A.Kawase, M.Iwaki, T.Hayakawa, T.Fujiwara et al. Enhanced safety profiles of the telomerase-specific replication-competent adenovirus by incorporation of normal cell-specific microRNA-targeted sequences. Clin Cancer Res 2011; 17:2807-18; PMID:21346145; http://dx.doi.org/10.1158/1078-0432.CCR-10-2008
37. E.J.Kelly, R.Nace, G.N.Barber, S.J.Russell. Attenuation of vesicular stomatitis virus encephalitis through microRNA targeting. J Virol 2010; 84:1550-62; PMID:19906911; http://dx.doi.org/10.1128/JVI.01788-09
38. R.E.Edge, T.J.Falls, C.W.Brown, B.D.Lichty, H.Atkins, J.C.Bell. A let-7 MicroRNA-sensitive vesicular stomatitis virus demonstrates tumor-specific replication. Mol Ther 2008; 16:1437-43; PMID:18560417; http://dx.doi.org/10.1038/mt.2008.130
39. E.J.Kelly, E.M.Hadac, S.Greiner, S.J.Russell. Engineering microRNA responsiveness to decrease virus pathogenicity. Nat Med 2008; 14:1278-83; PMID:18953352; http://dx.doi.org/10.1038/nm.1776
40. E.Callegari, B.K.Elamin, L.D'Abundo, S.Falzoni, G.Donvito, F.Moshiri, M.Milazzo, G.Altavilla, L.Giacomelli, F.Fornari et al. Anti-tumor activity of a miR-199-dependent oncolytic adenovirus. PLoS One 2013; 8:e73964; PMID:24069256; http://dx.doi.org/10.1371/journal.pone.0073964
41. J.M.Li, K.C.Kao, L.F.Li, T.M.Yang, C.P.Wu, Y.M.Horng, W.W.Jia, C.T.Yang. MicroRNA-145 regulates oncolytic herpes simplex virus-1 for selective killing of human non-small cell lung cancer cells. Virol J 2013; 10:241; PMID:23876001; http://dx.doi.org/10.1186/1743-422X-10-241
42. E.Ylosmaki, S.Lavilla-Alonso, S.Jaamaa, M.Vaha-Koskela, T.af Hallstrom, A.Hemminki, J.Arola, H.Mäkisalo, K.Saksela. MicroRNA-mediated suppression of oncolytic adenovirus replication in human liver. PLoS One 2013; 8:e54506; PMID:23349911; http://dx.doi.org/10.1371/journal.pone.0054506
43. X.Yang, E.Chen, H.Jiang, K.Muszynski, R.D.Harris, S.L.Giardina, M.Gromeier, G.Mitra, G.Soman. Evaluation of IRES-mediated, cell-type-specific cytotoxicity of poliovirus using a colorimetric cell proliferation assay. J Virol Methods 2009; 155:44-54; PMID:18951922; http://dx.doi.org/10.1016/j.jviromet.2008.09.020
44. A.Ammayappan, R.Nace, K.W.Peng, S.J.Russell. Neuroattenuation of vesicular stomatitis virus through picornaviral internal ribosome entry sites. J Virol 2013; 87:3217-28; PMID:23283963; http://dx.doi.org/10.1128/JVI.02984-12
45. C.Goetz, M.Gromeier. Preparing an oncolytic poliovirus recombinant for clinical application against glioblastoma multiforme. Cytokine Growth Factor Rev 2010; 21:197-203; PMID:20299272; http://dx.doi.org/10.1016/j.cytogfr.2010.02.005
46. H.Schipper, V.Alla, C.Meier, D.M.Nettelbeck, O.Herchenroder, B.M.Putzer. Eradication of metastatic melanoma through cooperative expression of RNA-based HDAC1 inhibitor and p73 by oncolytic adenovirus. Oncotarget 2014; 5:5893-907; PMID:25071017; http://dx.doi.org/10.18632/oncotarget.1839
47. B.J.Passer, T.Cheema, B.Zhou, H.Wakimoto, C.Zaupa, M.Razmjoo, J.Sarte, S.Wu, C.L.Wu, J.W.Noah et al. Identification of the ENT1 antagonists dipyridamole and dilazep as amplifiers of oncolytic herpes simplex virus-1 replication. Cancer Res 2010; 70:3890-5; PMID:20424118; http://dx.doi.org/10.1158/0008-5472.CAN-10-0155
48. C.Y.Lee, L.X.Bu, A.DeBenedetti, B.J.Williams, P.S.Rennie, W.W.Jia. Transcriptional and translational dual-regulated oncolytic herpes simplex virus type 1 for targeting prostate tumors. Mol Ther 2010; 18:929-35; PMID:20179676; http://dx.doi.org/10.1038/mt.2010.26
49. Y.Cuevas, R.Hernandez-Alcoceba, J.Aragones, S.Naranjo-Suarez, M.C.Castellanos, M.A.Esteban, S.Martín-Puig, M.O.Landazuri, L.del Peso. Specific oncolytic effect of a new hypoxia-inducible factor-dependent replicative adenovirus on von Hippel-Lindau-defective renal cell carcinomas. Cancer Res 2003; 63:6877-84; PMID:14583486
50. D.E.Post, E.G.Van Meir. A novel hypoxia-inducible factor (HIF) activated oncolytic adenovirus for cancer therapy. Oncogene 2003; 22:2065-72; PMID:12687009; http://dx.doi.org/10.1038/sj.onc.1206464
51. W.H.Lin, S.H.Yeh, W.J.Yang, K.H.Yeh, T.Fujiwara, A.Nii, S.S.Chang, P.J.Chen. Telomerase-specific oncolytic adenoviral therapy for orthotopic hepatocellular carcinoma in HBx transgenic mice. Int J Cancer 2013; 132:1451-62; PMID:22886913; http://dx.doi.org/10.1002/ijc.27770
52. H.Takahashi, H.Hyakusoku, C.Horii, M.Takahashi, G.Nishimura, T.Taguchi, N.Kondo, A.Sakakibara, Y.Urata, D.Sano. Telomerase-specific oncolytic adenovirus: Antitumor effects on radiation-resistant head and neck squamous cell carcinoma cells. Head Neck 2014; 36:411-8; PMID:23728900; http://dx.doi.org/10.1002/hed.23309
53. C.Jin, D.Yu, M.Cancer, B.Nilsson, J.Leja, M.Essand. Tat-PTD-modified oncolytic adenovirus driven by the SCG3 promoter and ASH1 enhancer for neuroblastoma therapy. Hum Gene Ther 2013; 24:766-75; PMID:23889332; http://dx.doi.org/10.1089/hum.2012.132
54. W.Wang, W.Ji, H.Hu, J.Ma, X.Li, W.Mei, Y.Xu, H.Hu, Y.Yan, Q.Song et al. Survivin promoter-regulated oncolytic adenovirus with Hsp70 gene exerts effective antitumor efficacy in gastric cancer immunotherapy. Oncotarget 2014; 5:150-60; PMID:24473833
55. R.Shobana, S.K.Samal, S.Elankumaran. Prostate-specific antigen-retargeted recombinant newcastle disease virus for prostate cancer virotherapy. J Virol 2013; 87:3792-800; PMID:23345509; http://dx.doi.org/10.1128/JVI.02394-12
56. H.K.Seo, J.B.Seo, J.K.Nam, K.C.Jeong, S.P.Shin, I.H.Kim, S.D.Lee, S.J.Lee. Development of replication-competent adenovirus for bladder cancer by controlling adenovirus E1a and E4 gene expression with the survivin promoter. Oncotarget 2014; 5:5615-23; PMID:25015402; http://dx.doi.org/10.18632/oncotarget.2151
57. W.Wang, W.Ji, H.Hu, J.Ma, X.Li, W.Mei, Y.Xu, H.Hu, Y.Yan, Q.Song et al. Survivin promoter-regulated oncolytic adenovirus with Hsp70 gene exerts effective antitumor efficacy in gastric cancer immunotherapy. Oncotarget 2014; 5:150-60; PMID:24473833; http://dx.doi.org/10.18632/oncotarget.1430
58. D.F.Stojdl, B.D.Lichty, B.R.tenOever, J.M.Paterson, A.T.Power, S.Knowles, R.Marius, J.Reynard, L.Poliquin, H.Atkins et al. VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell 2003; 4:263-75; PMID:14585354; http://dx.doi.org/10.1016/S1535-6108(03)00241-1
59. F.Sarinella, A.Calistri, P.Sette, G.Palu, C.Parolin. Oncolysis of pancreatic tumour cells by a gamma34.5-deleted HSV-1 does not rely upon Ras-activation, but on the PI 3-kinase pathway. Gene Ther 2006; 13:1080-7; PMID:16554839; http://dx.doi.org/10.1038/sj.gt.3302770
60. S.Krishnamurthy, T.Takimoto, R.A.Scroggs, A.Portner. Differentially regulated interferon response determines the outcome of Newcastle disease virus infection in normal and tumor cell lines. J Virol 2006; 80:5145-55; PMID:16698995; http://dx.doi.org/10.1128/JVI.02618-05
61. D.F.Stojdl, B.Lichty, S.Knowles, R.Marius, H.Atkins, N.Sonenberg, J.C.Bell. Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat Med 2000; 6:821-5; PMID:10888934; http://dx.doi.org/10.1038/77558
62. M.C.Coffey, J.E.Strong, P.A.Forsyth, P.W.Lee. Reovirus therapy of tumors with activated Ras pathway. Science 1998; 282:1332-4; PMID:9812900; http://dx.doi.org/10.1126/science.282.5392.1332
63. P.H.Cheng, X.M.Rao, K.M.McMasters, H.S.Zhou. Molecular basis for viral selective replication in cancer cells: activation of CDK2 by adenovirus-induced cyclin E. PLoS One 2013; 8:e57340; PMID:23437375; http://dx.doi.org/10.1371/journal.pone.0057340
64. K.Okemoto, B.Wagner, H.Meisen, A.Haseley, B.Kaur, E.A.Chiocca. STAT3 activation promotes oncolytic HSV1 replication in glioma cells. PLoS One 2013; 8:e71932; PMID:23936533; http://dx.doi.org/10.1371/journal.pone.0071932
65. R.Maitra, R.Seetharam, L.Tesfa, T.A.Augustine, L.Klampfer, M.C.Coffey, J.M.Mariadason, S.Goel. Oncolytic reovirus preferentially induces apoptosis in KRAS mutant colorectal cancer cells, and synergizes with irinotecan. Oncotarget 2014; 5:2807-19; PMID:24798549; http://dx.doi.org/10.18632/oncotarget.1921
66. J.Li, H.Liu, L.Li, H.Wu, C.Wang, Z.Yan, Y.Wang, C.Su, H.Jin, F.Zhou et al. The combination of an oxygen-dependent degradation domain-regulated adenovirus expressing the chemokine RANTES/CCL5 and NK-92 cells exerts enhanced antitumor activity in hepatocellular carcinoma. Oncol Rep 2013; 29:895-902; PMID:23292657; http://dx.doi.org/10.3892/or.2012.2217
67. L.A.Banaszynski, M.A.Sellmyer, C.H.Contag, T.J.Wandless, S.H.Thorne. Chemical control of protein stability and function in living mice. Nat Med 2008; 14:1123-7; PMID:18836461; http://dx.doi.org/10.1038/nm.1754
68. M.Glass, A.Busche, K.Wagner, M.Messerle, E.M.Borst. Conditional and reversible disruption of essential herpesvirus proteins. Nat Methods 2009; 6:577-9; PMID:19578384; http://dx.doi.org/10.1038/nmeth.1346
69. O.Wildner, R.M.Blaese, J.C.Morris. Therapy of colon cancer with oncolytic adenovirus is enhanced by the addition of herpes simplex virus-thymidine kinase. Cancer Res 1999; 59:410-3; PMID:9927055
70. J.C.Tseng, P.B.Zanzonico, B.Levin, R.Finn, S.M.Larson, D.Meruelo. Tumor-specific in vivo transfection with HSV-1 thymidine kinase gene using a Sindbis viral vector as a basis for prodrug ganciclovir activation and PET. J Nucl Med 2006; 47:1136-43; PMID:16818948
71. J.Foloppe, J.Kintz, N.Futin, A.Findeli, P.Cordier, Y.Schlesinger, C.Hoffmann, C.Tosch, J.M.Balloul, P.Erbs. Targeted delivery of a suicide gene to human colorectal tumors by a conditionally replicating vaccinia virus. Gene Ther 2008; 15:1361-71; PMID:18480846; http://dx.doi.org/10.1038/gt.2008.82
72. Y.Liu, A.Deisseroth. Oncolytic adenoviral vector carrying the cytosine deaminase gene for melanoma gene therapy. Cancer Gene Ther 2006; 13:845-55; PMID:16710344; http://dx.doi.org/10.1038/sj.cgt.7700962
73. S.Leveille, S.Samuel, M.L.Goulet, J.Hiscott. Enhancing VSV oncolytic activity with an improved cytosine deaminase suicide gene strategy. Cancer Gene Ther 2011; 18:435-43; PMID:21394109; http://dx.doi.org/10.1038/cgt.2011.14
74. X.Dong, W.Qu, S.Ma, Z.Zhu, C.Zheng, A.He, A.Karlsson, K.Xu, X.Zheng. Potent antitumoral effects of targeted promoter-driven oncolytic adenovirus armed with Dm-dNK for breast cancer in vitro and in vivo. Cancer Lett 2013; 328:95-103; PMID:23000515; http://dx.doi.org/10.1016/j.canlet.2012.09.003
75. A.D.Hartkopf, S.Bossow, J.Lampe, M.Zimmermann, F.A.Taran, D.Wallwiener, T.Fehm, M.Bitzer, U.M.Lauer. Enhanced killing of ovarian carcinoma using oncolytic measles vaccine virus armed with a yeast cytosine deaminase and uracil phosphoribosyltransferase. Gynecol Oncol 2013; 130:362-8; PMID:23676551; http://dx.doi.org/10.1016/j.ygyno.2013.05.004
76. J.Lampe, S.Bossow, T.Weiland, I.Smirnow, R.Lehmann, W.Neubert, M.Bitzer, U.M.Lauer. An armed oncolytic measles vaccine virus eliminates human hepatoma cells independently of apoptosis. Gene Ther 2013; 20:1033-41; PMID:23719065; http://dx.doi.org/10.1038/gt.2013.28
77. N.Shinoura, Y.Yoshida, A.Asai, T.Kirino, H.Hamada. Adenovirus-mediated transfer of p53 and Fas ligand drastically enhances apoptosis in gliomas. Cancer Gene Ther 2000; 7:732-8; PMID:10830720; http://dx.doi.org/10.1038/sj.cgt.7700160
78. L.Zhao, A.Dong, J.Gu, Z.Liu, Y.Zhang, W.Zhang, Y.Wang, L.He, C.Qian, Q.Qian et al. The antitumor activity of TRAIL and IL-24 with replicating oncolytic adenovirus in colorectal cancer. Cancer Gene Ther 2006; 13:1011-22; PMID:16799468; http://dx.doi.org/10.1038/sj.cgt.7700969
79. W.Zhu, H.Zhang, Y.Shi, M.Song, B.Zhu, L.Wei. Oncolytic adenovirus encoding tumor necrosis factor-related apoptosis inducing ligand (TRAIL) inhibits the growth and metastasis of triple-negative breast cancer. Cancer Biol Ther 2013; 14:1016-23; PMID:24025362; http://dx.doi.org/10.4161/cbt.26043
80. G.Jiang, J.Li, Z.Zeng, L.Xian. Lentivirus-mediated gene therapy by suppressing survivin in BALB/c nude mice bearing oral squamous cell carcinoma. Cancer Biol Ther 2006; 5:435-40; PMID:16575205; http://dx.doi.org/10.4161/cbt.5.4.2542
81. W.Shen, J.K.Tu, X.H.Wang, Z.X.Fu. Oncolytic adenovirus mediated Survivin RNA interference and 5-fluorouracil synergistically suppress the lymphatic metastasis of colorectal cancer. Oncol Rep 2010; 24:1285-90; PMID:20878122; http://dx.doi.org/10.3892/or_00000864
82. W.Shen, C.Y.Wang, X.H.Wang, Z.X.Fu. Oncolytic adenovirus mediated Survivin knockdown by RNA interference suppresses human colorectal carcinoma growth in vitro and in vivo. J Exp Clin Cancer Res 2009; 28:81; PMID:19527508; http://dx.doi.org/10.1186/1756-9966-28-81
83. Y.Tong, L.You, H.Liu, L.Li, H.Meng, Q.Qian, W.Qian. Potent antitumor activity of oncolytic adenovirus expressing Beclin-1 via induction of autophagic cell death in leukemia. Oncotarget 2013; 4:860-74; PMID:23765161; http://dx.doi.org/10.18632/oncotarget.1018
84. I.Fernandez-Ulibarri, K.Hammer, M.A.Arndt, J.K.Kaufmann, D.Dorer, S.Engelhardt, R.E.Kontermann, J.Hess, H.Allgayer, J.Krauss et al. Genetic delivery of an immunoRNase by an oncolytic adenovirus enhances anticancer activity. Int J Cancer 2015; 136:2228-40; PMID:25303768; http://dx.doi.org/10.1002/ijc.29258
85. J.G.Pol, L.Zhang, B.W.Bridle, K.B.Stephenson, J.Resseguier, S.Hanson, L.Chen, N.Kazdhan, J.L.Bramson, D.F.Stojdl et al. Maraba virus as a potent oncolytic vaccine vector. Mol Ther 2014; 22:420-9; PMID:24322333; http://dx.doi.org/10.1038/mt.2013.249
86. B.W.Bridle, L.Chen, C.G.Lemay, J.S.Diallo, J.Pol, A.Nguyen, A.Capretta, R.He, J.L.Bramson, J.C.Bell et al. HDAC inhibition suppresses primary immune responses, enhances secondary immune responses, and abrogates autoimmunity during tumor immunotherapy. Mol Ther 2013; 21:887-94; PMID:23295947; http://dx.doi.org/10.1038/mt.2012.265
87. B.W.Bridle, D.Clouthier, L.Zhang, J.Pol, L.Chen, B.D.Lichty, J.L.Bramson, Y.Wan. Oncolytic vesicular stomatitis virus quantitatively and qualitatively improves primary CD8 T-cell responses to anticancer vaccines. Oncoimmunology 2013; 2:e26013; PMID:24083086; http://dx.doi.org/10.4161/onci.26013
88. B.W.Bridle, K.B.Stephenson, J.E.Boudreau, S.Koshy, N.Kazdhan, E.Pullenayegum, J.Brunellière, J.L.Bramson, B.D.Lichty, Y.Wan. Potentiating cancer immunotherapy using an oncolytic virus. Mol Ther 2010; 184:4269-75; PMID:20551919; http://dx.doi.org/10.1038/mt.2010.98
89. B.W.Bridle, J.E.Boudreau, B.D.Lichty, J.Brunelliere, K.Stephenson, S.Koshy, J.L.Bramson, Y.Wan. Vesicular stomatitis virus as a novel cancer vaccine vector to prime antitumor immunity amenable to rapid boosting with adenovirus. Mol Ther 2009; 17:1814-21; PMID:19603003; http://dx.doi.org/10.1038/mt.2009.154
90. N.Woller, E.Gurlevik, C.I.Ureche, A.Schumacher, F.Kuhnel. Oncolytic viruses as anticancer vaccines. Front Oncol 2014; 4:188; PMID:25101244; http://dx.doi.org/10.3389/fonc.2014.00188
91. I.Diaconu, V.Cerullo, M.L.Hirvinen, S.Escutenaire, M.Ugolini, S.K.Pesonen, S.Bramante, S.Parviainen, A.Kanerva, A.S.Loskog et al. Immune response is an important aspect of the antitumor effect produced by a CD40L-encoding oncolytic adenovirus. Cancer Res 2012; 72:2327-38; PMID:22396493; http://dx.doi.org/10.1158/0008-5472.CAN-11-2975
92. S.Pesonen, I.Diaconu, L.Kangasniemi, T.Ranki, A.Kanerva, S.K.Pesonen, U.Gerdemann, A.M.Leen, K.Kairemo, M.Oksanen et al. Oncolytic immunotherapy of advanced solid tumors with a CD40L-expressing replicating adenovirus: assessment of safety and immunologic responses in patients. Cancer Res 2012; 72:1621-31; PMID:22323527; http://dx.doi.org/10.1158/0008-5472.CAN-11-3001
93. E.M.Gomes, M.S.Rodrigues, A.P.Phadke, L.D.Butcher, C.Starling, S.Chen, D.Chang, R.Hernandez-Alcoceba, J.T.Newman, M.J.Stone et al. Antitumor activity of an oncolytic adenoviral-CD40 ligand (CD154) transgene construct in human breast cancer cells. Clin Cancer Res 2009; 15:1317-25; PMID:19228733; http://dx.doi.org/10.1158/1078-0432.CCR-08-1360
94. K.J.Choi, J.H.Kim, Y.S.Lee, J.Kim, B.S.Suh, H.Kim, S.Cho, J.H.Sohn, G.E.Kim, C.O.Yun. Concurrent delivery of GM-CSF and B7-1 using an oncolytic adenovirus elicits potent antitumor effect. Gene Ther 2006; 13:1010-20; PMID:16525479; http://dx.doi.org/10.1038/sj.gt.3302759
95. S.Parviainen, M.Ahonen, I.Diaconu, M.Hirvinen, A.Karttunen, M.Vaha-Koskela, A.Hemminki, V.Cerullo. CD40 ligand and tdTomato-armed vaccinia virus for induction of antitumor immune response and tumor imaging. Gene Ther 2014; 21:195-204; PMID:24305418; http://dx.doi.org/10.1038/gt.2013.73
96. H.Wei, L.Zhao, I.Hellstrom, K.E.Hellstrom, Y.Guo. Dual targeting of CD137 co-stimulatory and PD-1 co-inhibitory molecules for ovarian cancer immunotherapy. Oncoimmunology 2014; 3:e28248; PMID:25050196; http://dx.doi.org/10.4161/onci.28248
97. L.J.Thomas, L.Z.He, H.Marsh, T.Keler. Targeting human CD27 with an agonist antibody stimulates T-cell activation and antitumor immunity. Oncoimmunology 2014; 3:e27255; PMID:24605266; http://dx.doi.org/10.4161/onci.27255
98. D.Zamarin, A.Vigil, K.Kelly, A.Garcia-Sastre, Y.Fong. Genetically engineered Newcastle disease virus for malignant melanoma therapy. Gene Ther 2009; 16:796-804; PMID:19242529; http://dx.doi.org/10.1038/gt.2009.14
99. Y.Takehara, T.Satoh, A.Nishizawa, K.Saeki, M.Nakamura, M.Masuzawa, Y.Kaneda, I.Katayama, H.Yokozeki. Anti-tumor effects of inactivated Sendai virus particles with an IL-2 gene on angiosarcoma. Clin Immunol 2013; 149:1-10; PMID:23886549; http://dx.doi.org/10.1016/j.clim.2013.05.019
100. M.Beyer. Interleukin-2 treatment of tumor patients can expand regulatory T cells. Oncoimmunology 2012; 1:1181-2; PMID:23170272; http://dx.doi.org/10.4161/onci.20639
101. R.J.Wong, M.K.Chan, Z.Yu, R.A.Ghossein, I.Ngai, P.S.Adusumilli, B.M.Stiles, J.P.Shah, B.Singh, Y.Fong. Angiogenesis inhibition by an oncolytic herpes virus expressing interleukin 12. Clin Cancer Res 2004; 10:4509-16; PMID:15240543; http://dx.doi.org/10.1158/1078-0432.CCR-04-0081
102. S.N.Zhang, I.K.Choi, J.H.Huang, J.Y.Yoo, K.J.Choi, C.O.Yun. Optimizing DC vaccination by combination with oncolytic adenovirus coexpressing IL-12 and GM-CSF. Mol Ther 2011; 19:1558-68; PMID:21468000; http://dx.doi.org/10.1038/mt.2011.29
103. J.N.Parker, G.Y.Gillespie, C.E.Love, S.Randall, R.J.Whitley, J.M.Markert. Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors. Proc Natl Acad Sci U S A 2000; 97:2208-13; PMID:10681459; http://dx.doi.org/10.1073/pnas.040557897
104. B.J.Passer, T.Cheema, S.Wu, C.L.Wu, S.D.Rabkin, R.L.Martuza. Combination of vinblastine and oncolytic herpes simplex virus vector expressing IL-12 therapy increases antitumor and antiangiogenic effects in prostate cancer models. Cancer Gene Ther 2013; 20:17-24; PMID:23138870; http://dx.doi.org/10.1038/cgt.2012.75
105. W.Zhang, G.Fulci, H.Wakimoto, T.A.Cheema, J.S.Buhrman, D.S.Jeyaretna, A.O.Stemmer Rachamimov, S.D.Rabkin, R.L.Martuza. Combination of oncolytic herpes simplex viruses armed with angiostatin and IL-12 enhances antitumor efficacy in human glioblastoma models. Neoplasia 2013; 15:591-9; PMID:23730207; http://dx.doi.org/10.1593/neo.13158
106. S.O.Freytag, K.N.Barton, Y.Zhang. Efficacy of oncolytic adenovirus expressing suicide genes and interleukin-12 in preclinical model of prostate cancer. Gene Ther 2013; 20:1131-9; PMID:23842593; http://dx.doi.org/10.1038/gt.2013.40
107. J.C.Roth, K.A.Cassady, J.J.Cody, J.N.Parker, K.H.Price, J.M.Coleman, J.O.Peggins, P.E.Noker, N.Powers, S.Grimes et al. Evaluation of the safety and biodistribution of M032, an attenuated HSV-1 virus expressing hIL-12, after intracerebral administration to aotus non-human primates. Hum Gene Ther Clin Dev 2014; PMID:24579875
108. M.Malvicini, L.Alaniz, J.Bayo, M.Garcia, F.Piccioni, E.Fiore, C.Atorrasagasti, J.B.Aquino, P.Matar, G.Mazzolini. Single low-dose cyclophosphamide combined with interleukin-12 gene therapy is superior to a metronomic schedule in inducing immunity against colorectal carcinoma in mice. Oncoimmunology 2012; 1:1038-47; PMID:23170252; http://dx.doi.org/10.4161/onci.20684
109. H.C.Wong, E.K.Jeng, P.R.Rhode. The IL-15-based superagonist ALT-803 promotes the antigen-independent conversion of memory CD8 T cells into innate-like effector cells with antitumor activity. Oncoimmunology 2013; 2:e26442; PMID:24404427; http://dx.doi.org/10.4161/onci.26442
110. K.B.Stephenson, N.G.Barra, E.Davies, A.A.Ashkar, B.D.Lichty. Expressing human interleukin-15 from oncolytic vesicular stomatitis virus improves survival in a murine metastatic colon adenocarcinoma model through the enhancement of anti-tumor immunity. Cancer Gene Ther 2012; 19:238-46; PMID:22158521; http://dx.doi.org/10.1038/cgt.2011.81
111. J.Liu, S.Wennier, M.Reinhard, E.Roy, A.MacNeill, G.McFadden. Myxoma virus expressing interleukin-15 fails to cause lethal myxomatosis in European rabbits. J Virol 2009; 83:5933-8; PMID:19279088; http://dx.doi.org/10.1128/JVI.00204-09
112. M.van Rikxoort, M.Michaelis, M.Wolschek, T.Muster, A.Egorov, J.Seipelt, H.W.Doerr, J.CinatlJr. Oncolytic effects of a novel influenza A virus expressing interleukin-15 from the NS reading frame. PLoS One 2012; 7:e36506; PMID:22563505; http://dx.doi.org/10.1371/journal.pone.0036506
113. D.C.Gaston, C.I.Odom, L.Li, J.M.Markert, J.C.Roth, K.A.Cassady, R.J.Whitley, J.N.Parker. Production of bioactive soluble interleukin-15 in complex with interleukin-15 receptor alpha from a conditionally-replicating oncolytic HSV-1. PLoS One 2013; 8:e81768; PMID:24312353; http://dx.doi.org/10.1371/journal.pone.0081768
114. M.Vincent, A.Quemener, Y.Jacques. Antitumor activity of an immunocytokine composed of an anti-GD2 antibody and the IL-15 superagonist RLI. Oncoimmunology 2013; 2:e26441; PMID:24349876; http://dx.doi.org/10.4161/onci.26441
115. I.K.Choi, Y.Li, E.Oh, J.Kim, C.O.Yun. Oncolytic adenovirus expressing IL-23 and p35 elicits IFN-gamma- and TNF-alpha-co-producing T cell-mediated antitumor immunity. PLoS One 2013; 8:e67512; PMID:23844018; http://dx.doi.org/10.1371/journal.pone.0067512
116. G.Jiang, A.J.Jiang, Q.Cheng, H.Tian, L.T.Li, J.N.Zheng. A dual-regulated oncolytic adenovirus expressing interleukin-24 sensitizes melanoma cells to temozolomide via the induction of apoptosis. Tumour Biol 2013; 34:1263-71; PMID:23430584; http://dx.doi.org/10.1007/s13277-013-0701-7
117. W.Lou, Q.Chen, L.Ma, J.Liu, Z.Yang, J.Shen, Y.Cui, X.W.Bian, C.Qian. Oncolytic adenovirus co-expressing miRNA-34a and IL-24 induces superior antitumor activity in experimental tumor model. J Mol Med (Berl) 2013; 91:715-25; PMID:23292172; http://dx.doi.org/10.1007/s00109-012-0985-x
118. B.He, X.Huang, X.Liu, B.Xu. Cancer targeting gene-viro-therapy for pancreatic cancer using oncolytic adenovirus ZD55-IL-24 in immune-competent mice. Mol Biol Rep 2013; 40:5397-405; PMID:23666064; http://dx.doi.org/10.1007/s11033-013-2638-8
119. L.Fang, Q.Cheng, J.Bai, Y.D.Qi, J.J.Liu, L.T.Li, J.N.Zheng. An oncolytic adenovirus expressing interleukin-24 enhances antitumor activities in combination with paclitaxel in breast cancer cells. Mol Med Rep 2013; 8:1416-24; PMID:24042845; http://dx.doi.org/10.3892/mmr.2013.1680
120. S.Pesonen, I.Diaconu, V.Cerullo, S.Escutenaire, M.Raki, L.Kangasniemi, P.Nokisalmi, G.Dotti, K.Guse, L.Laasonen et al. Integrin targeted oncolytic adenoviruses Ad5-D24-RGD and Ad5-RGD-D24-GMCSF for treatment of patients with advanced chemotherapy refractory solid tumors. Int J Cancer 2012; 130:1937-47; PMID:21630267; http://dx.doi.org/10.1002/ijc.26216
121. J.M.Burke, D.L.Lamm, M.V.Meng, J.J.Nemunaitis, J.J.Stephenson, J.C.Arseneau, J.Aimi, S.Lerner, A.W.Yeung, A.W.Kazarian et al. A first in human phase 1 study of CG0070, a GM-CSF expressing oncolytic adenovirus, for the treatment of nonmuscle invasive bladder cancer. J Urol 2012; 188:2391-7; PMID:23088985; http://dx.doi.org/10.1016/j.juro.2012.07.097
122. J.Heo, T.Reid, L.Ruo, C.J.Breitbach, S.Rose, M.Bloomston, M.Cho, H.Y.Lim, H.C.Chung, C.W.Kim et al. Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nat Med 2013; 19:329-36; PMID:23396206; http://dx.doi.org/10.1038/nm.3089
123. S.H.Thorne. The role of GM-CSF in enhancing immunotherapy of cancer. Immunotherapy 2013; 5:817-9; PMID:23902549; http://dx.doi.org/10.2217/imt.13.65
124. C.Grossardt, C.E.Engeland, S.Bossow, N.Halama, K.Zaoui, M.F.Leber, C.Springfeld, D.Jaeger, C.von Kalle, G.Ungerechts. Granulocyte-macrophage colony-stimulating factor-armed oncolytic measles virus is an effective therapeutic cancer vaccine. Hum Gene Ther 2013; 24:644-54; PMID:23642239; http://dx.doi.org/10.1089/hum.2012.205
125. H.Liu, S.J.Yuan, Y.T.Chen, Y.B.Xie, L.Cui, W.Z.Yang, D.X.Yang, Y.T.Tian. Preclinical evaluation of herpes simplex virus armed with granulocyte-macrophage colony-stimulating factor in pancreatic carcinoma. World J Gastroenterol 2013; 19:5138-43; PMID:23964149; http://dx.doi.org/10.3748/wjg.v19.i31.5138
126. N.K.Egilmez, J.L.Harden, R.B.Rowswell-Turner. Chemoimmunotherapy as long-term maintenance therapy for cancer. Oncoimmunology 2012; 1:563-5; PMID:22754788; http://dx.doi.org/10.4161/onci.19369
127. S.Dempe, M.Lavie, S.Struyf, R.Bhat, H.Verbeke, S.Paschek, N.Berghmans, R.Geibig, J.Rommelaere, J.Van Damme et al. Antitumoral activity of parvovirus-mediated IL-2 and MCP-3/CCL7 delivery into human pancreatic cancer: implication of leucocyte recruitment. Cancer Immunol Immunother 2012; 61:2113-23; PMID:22576056; http://dx.doi.org/10.1007/s00262-012-1279-4
128. J.Li, M.O'Malley, P.Sampath, P.Kalinski, D.L.Bartlett, S.H.Thorne. Expression of CCL19 from oncolytic vaccinia enhances immunotherapeutic potential while maintaining oncolytic activity. Neoplasia 2012; 14:1115-21; PMID:23308044; http://dx.doi.org/10.1593/neo.121272
129. O.J.Kwon, E.Kang, J.W.Choi, S.W.Kim, C.O.Yun. Therapeutic targeting of chitosan-PEG-folate-complexed oncolytic adenovirus for active and systemic cancer gene therapy. J Control Release 2013; 169:257-65; PMID:23562633; http://dx.doi.org/10.1016/j.jconrel.2013.03.030
130. T.Shikano, H.Kasuya, T.T.Sahin, N.Nomura, A.Kanzaki, M.Misawa, Y.Nishikawa, T.Shirota, S.Yamada, T.Fujii et al. High therapeutic potential for systemic delivery of a liposome-conjugated herpes simplex virus Curr Cancer Drug Targets 2011; 11:111-22; PMID:21062239; http://dx.doi.org/10.2174/156800911793743673
131. N.K.Green, A.Hale, R.Cawood, S.Illingworth, C.Herbert, T.Hermiston, V.Subr, K.Ulbrich, N.van Rooijen, L.W.Seymour et al. Tropism ablation and stealthing of oncolytic adenovirus enhances systemic delivery to tumors and improves virotherapy of cancer. Nanomedicine (Lond) 2012; 7:1683-95; PMID:22709345; http://dx.doi.org/10.2217/nnm.12.50
132. M.Muthana, S.Rodrigues, Y.Y.Chen, A.Welford, R.Hughes, S.Tazzyman, M.Essand, F.Morrow, C.E.Lewis. Macrophage delivery of an oncolytic virus abolishes tumor regrowth and metastasis after chemotherapy or irradiation. Cancer Res 2013; 73:490-5; PMID:23172310; http://dx.doi.org/10.1158/0008-5472.CAN-12-3056
133. R.A.Adair, K.J.Scott, S.Fraser, F.Errington-Mais, H.Pandha, M.Coffey, P.Selby, G.P.Cook, R.Vile, K.J.Harrington et al. Cytotoxic and immune-mediated killing of human colorectal cancer by reovirus-loaded blood and liver mononuclear cells. Int J Cancer 2013; 132:2327-38; PMID:23114986; http://dx.doi.org/10.1002/ijc.27918
134. S.Eisenstein, B.A.Coakley, K.Briley-Saebo, G.Ma, H.M.Chen, M.Meseck, S.Ward, C.Divino, S.Woo, S.H.Chen et al. Myeloid-derived suppressor cells as a vehicle for tumor-specific oncolytic viral therapy. Cancer Res 2013; 73:5003-15; PMID:23536556; http://dx.doi.org/10.1158/0008-5472.CAN-12-1597
135. P.Y.Pan, H.M.Chen, S.H.Chen. Myeloid-derived suppressor cells as a Trojan horse: A cellular vehicle for the delivery of oncolytic viruses. Oncoimmunology 2013; 2:e25083; PMID:24083075; http://dx.doi.org/10.4161/onci.25083
136. E.K.Mader, G.Butler, S.C.Dowdy, A.Mariani, K.L.Knutson, M.J.Federspiel, S.J.Russell, E.Galanis, A.B.Dietz, K.W.Peng. Optimizing patient derived mesenchymal stem cells as virus carriers for a phase I clinical trial in ovarian cancer. J Transl Med 2013; 11:20; PMID:23347343; http://dx.doi.org/10.1186/1479-5876-11-20
137. H.T.Ong, M.J.Federspiel, C.M.Guo, L.L.Ooi, S.J.Russell, K.W.Peng, K.M.Hui. Systemically delivered measles virus-infected mesenchymal stem cells can evade host immunity to inhibit liver cancer growth. J Hepatol 2013; 59:999-1006; PMID:23867315; http://dx.doi.org/10.1016/j.jhep.2013.07.010
138. A.Castleton, A.Dey, B.Beaton, B.Patel, A.Aucher, D.M.Davis, A.K.Fielding. Human mesenchymal stromal cells deliver systemic oncolytic measles virus to treat acute lymphoblastic leukemia in the presence of humoral immunity. Blood 2014; 123:1327-35; PMID:24345754; http://dx.doi.org/10.1182/blood-2013-09-528851
139. J.Chisholm, K.Howe, M.Taj, M.Zambon. Influenza immunisation in children with solid tumours. Eur J Cancer 2005; 41:2280-7; PMID:16143516; http://dx.doi.org/10.1016/j.ejca.2005.07.006
140. C.D.Cooksley, E.B.Avritscher, B.N.Bekele, K.V.Rolston, J.M.Geraci, L.S.Elting. Epidemiology and outcomes of serious influenza-related infections in the cancer population. Cancer 2005; 104:618-28; PMID:15973737; http://dx.doi.org/10.1002/cncr.21203
141. K.L.Hicks, R.F.Chemaly, D.P.Kontoyiannis. Common community respiratory viruses in patients with cancer: more than just "common colds". Cancer 2003; 97:2576-87; PMID:12733157; http://dx.doi.org/10.1002/cncr.11353
142. J.Nemunaitis, F.Khuri, I.Ganly, J.Arseneau, M.Posner, E.Vokes, J.Kuhn, T.McCarty, S.Landers, A.Blackburn et al. Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. J Clin Oncol 2001; 19:289-98; PMID:11208818
143. S.K.Geevarghese, D.A.Geller, H.A.de Haan, M.Horer, A.E.Knoll, A.Mescheder, T.R.Reid, D.Y.Sze, K.K.Tanabe, H.Tawfik et al. Phase I/II study of oncolytic herpes simplex virus NV1020 in patients with extensively pretreated refractory colorectal cancer metastatic to the liver. Hum Gene Ther 2010; 21:1119-28; PMID:20486770; http://dx.doi.org/10.1089/hum.2010.020
144. S.Hacein-Bey-Abina, C.von Kalle, M.Schmidt, F.Le Deist, N.Wulffraat, E.McIntyre, I.Radford, J.L.Villeval, C.C.Fraser, M.Cavazzana-Calvo et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 2003; 348:255-6; PMID:12529469; http://dx.doi.org/10.1056/NEJM200301163480314
145. S.Hacein-Bey-Abina, C.Von Kalle, M.Schmidt, M.P.McCormack, N.Wulffraat, P.Leboulch, A.Lim, C.S.Osborne, R.Pawliuk, E.Morillon et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003; 302:415-9; PMID:14564000; http://dx.doi.org/10.1126/science.1088547
146. L.Zitvogel, L.Galluzzi, M.J.Smyth, G.Kroemer. Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. Immunity 2013; 39:74-88; PMID:23890065; http://dx.doi.org/10.1016/j.immuni.2013.06.014
147. L.Galluzzi, G.Kroemer, A.Eggermont. Novel immune checkpoint blocker approved for the treatment of advanced melanoma. Oncoimmunology 2014; 3:e967147; PMID:25941597; http://dx.doi.org/10.4161/21624011.2014.967147
148. L.Galluzzi, L.Senovilla, L.Zitvogel, G.Kroemer. The secret ally: immunostimulation by anticancer drugs. Nat Rev Drug Discov 2012; 11:215-33; PMID:22301798; http://dx.doi.org/10.1038/nrd3626
149. L.Galluzzi, E.Vacchelli, J.M.Bravo-San Pedro, A.Buque, L.Senovilla, E.E.Baracco, N.Bloy, F.Castoldi, J.P.Abastado, P.Agostinis et al. Classification of current anticancer immunotherapies. Oncotarget 2014; 5:12472-508; PMID:25537519; http://dx.doi.org/10.18632/oncotarget.2998
150. O.Kepp, L.Senovilla, I.Vitale, E.Vacchelli, S.Adjemian, P.Agostinis, L.Apetoh, F.Aranda, V.Barnaba, N.Bloy et al. Consensus guidelines for the detection of immunogenic cell death. Oncoimmunology 2014; 3:e955691; PMID:25941621; http://dx.doi.org/10.4161/21624011.2014.955691
151. C.E.Engeland, C.Grossardt, R.Veinalde, S.Bossow, D.Lutz, J.K.Kaufmann, I.Shevchenko, V.Umansky, D.M.Nettelbeck, W.Weichert et al. CTLA-4 and PD-L1 checkpoint blockade enhances oncolytic measles virus therapy. Mol Ther 2014; 22:1949-59; PMID:25156126; http://dx.doi.org/10.1038/mt.2014.160
152. J.Rojas, P.Sampath, W.Hou, S.H.Thorne. Defining effective combinations of immune checkpoint blockade and oncolytic virotherapy. Clin Cancer Res 2015; 21:5543-51; PMID:26187615; http://dx.doi.org/10.1158/1078-0432.CCR-14-200
153. V.Cerullo, A.Koski, M.Vaha-Koskela, A.Hemminki. Chapter eight–Oncolytic adenoviruses for cancer immunotherapy: data from mice, hamsters, and humans. Adv Cancer Res 2012; 115:265-318; PMID:23021247; http://dx.doi.org/10.1016/B978-0-12-398342-8.00008-2
154. M.Liang. Clinical development of oncolytic viruses in China. Curr Pharm Biotechnol 2012; 13:1852-7; PMID:21740357; http://dx.doi.org/10.2174/138920112800958760
155. J.K.Raty, J.T.Pikkarainen, T.Wirth, S.Yla-Herttuala. Gene therapy: the first approved gene-based medicines, molecular mechanisms and clinical indications. Curr Mol Pharmacol 2008; 1:13-23; PMID:20021420; http://dx.doi.org/10.2174/1874467210801010013
156. E.Dolgin. Oncolytic viruses get a boost with first FDA-approval recommendation. Nat Rev Drug Discov 2015; 14:369-71; PMID:26027526; http://dx.doi.org/10.1038/nrd4643
157. D.Killock. Skin cancer: T-VEC oncolytic viral therapy shows promise in melanoma. Nat Rev Clin Oncol 2015; 12:438; PMID:26077044; http://dx.doi.org/10.1038/nrclinonc.2015.106
158. N.Dharmadhikari, J.M.Mehnert, H.L.Kaufman. Oncolytic virus immunotherapy for melanoma. Curr Treat Options Oncol 2015; 16:326; PMID:25777572; http://dx.doi.org/10.1007/s11864-014-0326-0
159. F.J.Kohlhapp, A.Zloza, H.L.Kaufman. Talimogene laherparepvec (T-VEC) as cancer immunotherapy. Drugs Today (Barc) 2015; 51:549-58; PMID:26488034; http://dx.doi.org/10.1358/dot.2015.51.9.2383044
160. D.B.Johnson, I.Puzanov, M.C.Kelley. Talimogene laherparepvec (T-VEC) for the treatment of advanced melanoma. Immunotherapy 2015; 7:611-9; PMID:26098919; http://dx.doi.org/10.2217/imt.15.35
161. R.H.Andtbacka, H.L.Kaufman, F.Collichio, T.Amatruda, N.Senzer, J.Chesney, K.A.Delman, L.E.Spitler, I.Puzanov, S.S.Agarwala et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol 2015; 33:2780-8; PMID:26014293; http://dx.doi.org/10.1200/JCO.2014.58.3377
162. H.Kaufman, T.Amatruda, J.J.Nemunaitis, J.A.Chesney, K.A.Delman, L.E.Spitler, F.A.Collichio, M.I.Ross, Y.Zhang, M.Shilkrut et al. Tumor size and clinical outcomes in melanoma patients (MEL pts) treated with talimogene laherparepvec (T-VEC). ASCO Meeting Abstracts 2015; 33:9074
163. F.Aranda, E.Vacchelli, A.Eggermont, J.Galon, W.H.Fridman, L.Zitvogel, G.Kroemer, L.Galluzzi. Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapy. Oncoimmunology 2014; 3:e27297; PMID:24701370; http://dx.doi.org/10.4161/onci.27297
164. A.Buque, N.Bloy, F.Aranda, F.Castoldi, A.Eggermont, I.Cremer, W.H.Fridman, J.Fucikova, J.Galon, A.Marabelle et al. Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications. Oncoimmunology 2015; 4:e1008814; PMID:26137403; http://dx.doi.org/10.1080/2162402X.2015.1008814
165. I.Puzanov, M.M.Milhem, R.H.I.Andtbacka, D.R.Minor, O.Hamid, A.Li, J.Chou, H.Kaufman. Survival, safety, and response patterns in a phase 1b multicenter trial of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) in previously untreated, unresected stage IIIB-IV melanoma. ASCO Meeting Abstracts 2015; 33:9063
166. L.Vidal, H.S.Pandha, T.A.Yap, C.L.White, K.Twigger, R.G.Vile, A.Melcher, M.Coffey, K.J.Harrington, J.S.DeBono. A phase I study of intravenous oncolytic reovirus type 3 Dearing in patients with advanced cancer. Clin Cancer Res 2008; 14:7127-37; PMID:18981012; http://dx.doi.org/10.1158/1078-0432.CCR-08-0524
167. K.P.Kicielinski, E.A.Chiocca, J.S.Yu, G.M.Gill, M.Coffey, J.M.Markert. Phase 1 clinical trial of intratumoral reovirus infusion for the treatment of recurrent malignant gliomas in adults. Mol Ther 2014; 22:1056-62; PMID:24553100; http://dx.doi.org/10.1038/mt.2014.21
168. D.W.Sborov, G.J.Nuovo, A.Stiff, T.Mace, G.B.Lesinski, D.M.Benson, Jr., Y.A.Efebera, A.E.Rosko, F.Pichiorri, M.R.Grever et al. A phase I trial of single-agent reolysin in patients with relapsed multiple myeloma. Clin Cancer Res 2014; 20:5946-55; PMID:25294913; http://dx.doi.org/10.1158/1078-0432.CCR-14-1404
169. G.M.Weir, O.Hrytsenko, M.M.Stanford, N.L.Berinstein, M.Karkada, R.S.Liwski, M.Mansour. Metronomic cyclophosphamide enhances HPV16E7 peptide vaccine induced antigen-specific and cytotoxic T-cell mediated antitumor immune response. Oncoimmunology 2014; 3:e953407; PMID:25960932; http://dx.doi.org/10.4161/21624011.2014.953407
170. H.Sheng Sow, S.R.Mattarollo. Combining low-dose or metronomic chemotherapy with anticancer vaccines: A therapeutic opportunity for lymphomas. Oncoimmunology 2013; 2:e27058; PMID:24498564; http://dx.doi.org/10.4161/onci.27058
171. E.A.Kolb, V.Sampson, D.Stabley, A.Walter, K.Sol-Church, T.Cripe, P.Hingorani, C.H.Ahern, B.J.Weigel, J.Zwiebel et al. A phase I trial and viral clearance study of reovirus (Reolysin) in children with relapsed or refractory extra-cranial solid tumors: a Children's Oncology Group Phase I Consortium report. Pediatr Blood Cancer 2015; 62:751-8; PMID:25728527; http://dx.doi.org/10.1002/pbc.25464
172. V.Roulstone, K.Khan, H.S.Pandha, S.Rudman, M.Coffey, G.M.Gill, A.A.Melcher, R.Vile, K.J.Harrington, J.de Bono et al. Phase I trial of cyclophosphamide as an immune modulator for optimizing oncolytic reovirus delivery to solid tumors. Clin Cancer Res 2015; 21:1305-12; PMID:25424857; http://dx.doi.org/10.1158/1078-0432.CCR-14-1770
173. G.G.Au, A.M.Lindberg, R.D.Barry, D.R.Shafren. Oncolysis of vascular malignant human melanoma tumors by Coxsackievirus A21. Int J Oncol 2005; 26:1471-6; PMID:15870858; http://dx.doi.org/10.3892/ijo.26.6.1471
174. R.H.Andtbacka, B.Curti, S.Hallmeyer, D.R.Shafren. Phase II CALM study: Changes in the tumor microenvironment induced by the immunotherapeutic agent coxsackievirus A21 delivered intratumorally in patients with advanced melanoma. Cancer Res 2015; 75:Abstract CT214
175. R.H.I.Andtbacka, B.D.Curti, H.Kaufman, G.A.Daniels, J.J.Nemunaitis, L.E.Spitler, S.Hallmeyer, J.Lutzky, S.M.Schultz, E.D.Whitman, K.Zhou et al. Final data from CALM: A phase II study of Coxsackievirus A21 (CVA21) oncolytic virus immunotherapy in patients with advanced melanoma. ASCO Meeting Abstracts 2015; 33:9030
176. H.Pandha, K.Harrington, C.Ralph, A.Melcher, D.R.Shafren. Intravenous delivery of a novel oncolytic immunotherapy agent, CAVATAK, in advanced cancer patients. Cancer Res 2015; 75:Abstract CT205; http://dx.doi.org/10.1158/1538-7445.AM2015-CT205
177. S.Bramante, A.Koski, A.Kipar, I.Diaconu, I.Liikanen, O.Hemminki, L.Vassilev, S.Parviainen, V.Cerullo, S.K.Pesonen et al. Serotype chimeric oncolytic adenovirus coding for GM-CSF for treatment of sarcoma in rodents and humans. Int J Cancer 2014; 135:720-30; PMID:24374597; http://dx.doi.org/10.1002/ijc.28696
178. T.Ranki, T.Joensuu, E.Jager, J.Karbach, C.Wahle, K.Kairemo, T.Alanko, K.Partanen, R.Turkki, N.Linder et al. Local treatment of a pleural mesothelioma tumor with ONCOS-102 induces a systemic antitumor CD8 T-cell response, prominent infiltration of CD8 lymphocytes and Th1 type polarization. Oncoimmunology 2014; 3:e958937; PMID:25941579; http://dx.doi.org/10.4161/21624011.2014.958937
179. S.Bramante, J.K.Kaufmann, V.Veckman, I.Liikanen, D.M.Nettelbeck, O.Hemminki, L.Vassilev, V.Cerullo, M.Oksanen, R.Heiskanen et al. Treatment of melanoma with a serotype 5/3 chimeric oncolytic adenovirus coding for GM-CSF: Results in vitro, in rodents and in humans. Int J Cancer 2015; 137:1775-83; PMID:25821063; http://dx.doi.org/10.1002/ijc.29536
180. A.Kanerva, A.Koski, I.Liikanen, M.Oksanen, T.Joensuu, O.Hemminki, J.Palmgren, K.Hemminki, A.Hemminki. Case-control estimation of the impact of oncolytic adenovirus on the survival of patients with refractory solid tumors. Mol Ther 2015; 23:321-9; PMID:25381801; http://dx.doi.org/10.1038/mt.2014.218
181. O.Hemminki, S.Parviainen, J.Juhila, R.Turkki, N.Linder, J.Lundin, M.Kankainen, A.Ristimäki, A.Koski, I.Liikanen et al. Immunological data from cancer patients treated with Ad5/3-E2F-Delta24-GMCSF suggests utility for tumor immunotherapy. Oncotarget 2015; 6:4467-81; PMID:25714011; http://dx.doi.org/10.18632/oncotarget.2901
182. S.A.Pesonen, T.Ranki, E.Jager, J.Karbach, C.Wahle, T.K.Joensuu, T.Alanko, K.Partanen, K.Kairemo, R.Turkki et al. An evaluation of local and systemic immune markers following intratumoral administration of a chimeric adenovirus Ad5/3-D24-GMCSF in refractory cancer patients with solid tumors. ASCO Meeting Abstracts 2015; 33:3085
183. B.H.Park, T.Hwang, T.C.Liu, D.Y.Sze, J.S.Kim, H.C.Kwon, S.Y.Oh, S.Y.Han, J.H.Yoon, S.H.Hong et al. Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial. Lancet Oncol 2008; 9:533-42; PMID:18495536; http://dx.doi.org/10.1016/S1470-2045(08)70107-4
184. S.H.Park, C.J.Breitbach, J.Lee, J.O.Park, H.Y.Lim, W.K.Kang, A.Moon, J.H.Mun, E.M.Sommermann, L.Maruri Avidal et al. Phase 1b Trial of Biweekly Intravenous Pexa-Vec (JX-594), an Oncolytic and Immunotherapeutic Vaccinia Virus in Colorectal Cancer. Mol Ther 2015; 23:1532-40; PMID:26073886; http://dx.doi.org/10.1038/mt.2015.109
185. T.P.Cripe, M.C.Ngo, J.I.Geller, C.U.Louis, M.A.Currier, J.M.Racadio, A.J.Towbin, C.M.Rooney, A.Pelusio, A.Moon et al. Phase 1 study of intratumoral Pexa-Vec (JX-594), an oncolytic and immunotherapeutic vaccinia virus, in pediatric cancer patients. Mol Ther 2015; 23:602-8; PMID:25531693; http://dx.doi.org/10.1038/mt.2014.243
186. H.Wang, N.G.Chen, B.R.Minev, A.A.Szalay. Oncolytic vaccinia virus GLV-1h68 strain shows enhanced replication in human breast cancer stem-like cells in comparison to breast cancer cells. J Transl Med 2012; 10:167; PMID:22901246; http://dx.doi.org/10.1186/1479-5876-10-167
187. L.M.Krug, M.G.Zauderer, P.S.Adusumili, E.McGee, K.Sepkowitz, M.Klang, Y.A.Yu, P.Scigalla, V.W.Rusch. Phase I study of intra-pleural administration of GL-ONC1, an oncolytic vaccinia virus, in patients with malignant pleural effusion. ASCO Meeting Abstracts 2015; 33:7559
188. K.Kono, K.Mimura. Immunogenic tumor cell death induced by chemoradiotherapy in a clinical setting. Oncoimmunology 2013; 2:e22197; PMID:23482346; http://dx.doi.org/10.4161/onci.22197
189. E.B.Golden, D.Frances, I.Pellicciotta, S.Demaria, M.Helen Barcellos-Hoff, S.C.Formenti. Radiation fosters dose-dependent and chemotherapy-induced immunogenic cell death. Oncoimmunology 2014; 3:e28518; PMID:25071979; http://dx.doi.org/10.4161/onci.28518
190. L.K.Mell, Y.A.Yu, K.T.Brumund, G.A.Daniels, S.J.Advani, R.A.Weisman, P.R.Sanghvi, P.J.Martin, M.E.Wright, S.J.Onyeama et al. Phase I trial of intravenous attenuated vaccinia virus (GL-ONC1) with concurrent chemoradiotherapy (CRT) for locoregionally advanced head and neck carcinoma. ASCO Meeting Abstracts 2015; 33:6026
191. D.A.Kooby, J.F.Carew, M.W.Halterman, J.E.Mack, J.R.Bertino, L.H.Blumgart, H.J.Federoff, Y.Fong. Oncolytic viral therapy for human colorectal cancer and liver metastases using a multi-mutated herpes simplex virus type-1 (G207). FASEB J 1999; 13:1325-34; PMID:10428757
192. J.M.Markert, S.N.Razdan, H.C.Kuo, A.Cantor, A.Knoll, M.Karrasch, L.B.Nabors, M.Markiewicz, B.S.Agee, J.M.Coleman et al. A phase 1 trial of oncolytic HSV-1, G207, given in combination with radiation for recurrent GBM demonstrates safety and radiographic responses. Mol Ther 2014; 22:1048-55; PMID:24572293; http://dx.doi.org/10.1038/mt.2014.22
193. C.L.Morton, P.J.Houghton, E.A.Kolb, R.Gorlick, C.P.Reynolds, M.H.Kang, J.M.Maris, S.T.Keir, J.Wu, M.A.Smith. Initial testing of the replication competent Seneca Valley virus (NTX-010) by the pediatric preclinical testing program. Pediatr Blood Cancer 2010; 55:295-303; PMID:20582972; http://dx.doi.org/10.1002/pbc.22535
194. M.J.Burke, C.Ahern, B.J.Weigel, J.T.Poirier, C.M.Rudin, Y.Chen, T.P.Cripe, M.B.Bernhardt, S.M.Blaney. Phase I trial of Seneca Valley Virus (NTX-010) in children with relapsed/refractory solid tumors: a report of the Children's Oncology Group. Pediatr Blood Cancer 2015; 62:743-50; PMID:25307519; http://dx.doi.org/10.1002/pbc.25269
195. K.N.Barton, D.Paielli, Y.Zhang, S.Koul, S.L.Brown, M.Lu, J.Seely, J.H.Kim, S.O.Freytag. Second-generation replication-competent oncolytic adenovirus armed with improved suicide genes and ADP gene demonstrates greater efficacy without increased toxicity. Mol Ther 2006; 13:347-56; PMID:16290236; http://dx.doi.org/10.1016/j.ymthe.2005.10.005
196. E.Vacchelli, I.Vitale, E.Tartour, A.Eggermont, C.Sautes-Fridman, J.Galon, L.Zitvogel, G.Kroemer, L.Galluzzi. Trial Watch: Anticancer radioimmunotherapy. Oncoimmunology 2013; 2:e25595; PMID:24319634; http://dx.doi.org/10.4161/onci.25595
197. N.Bloy, J.Pol, G.Manic, I.Vitale, A.Eggermont, J.Galon, E.Tartour, L.Zitvogel, G.Kroemer, L.Galluzzi. Trial Watch: Radioimmunotherapy for oncological indications. Oncoimmunology 2014; 3:e954929; PMID:25941606; http://dx.doi.org/10.4161/21624011.2014.954929
198. S.O.Freytag, H.Stricker, M.Lu, M.Elshaikh, I.Aref, D.Pradhan, K.Levin, J.H.Kim, J.Peabody, F.Siddiqui et al. Prospective randomized phase 2 trial of intensity modulated radiation therapy with or without oncolytic adenovirus-mediated cytotoxic gene therapy in intermediate-risk prostate cancer. Int J Radiat Oncol Biol Phys 2014; 89:268-76; PMID:24837889; http://dx.doi.org/10.1016/j.ijrobp.2014.02.034
199. H.Kimata, H.Takakuwa, F.Goshima, O.Teshigahara, A.Nakao, T.Kurata, T.Sata, Y.Nishiyama. Effective treatment of disseminated peritoneal colon cancer with new replication-competent herpes simplex viruses. Hepatogastroenterology 2003; 50:961-6; PMID:12845959
200. H.Kasuya, Y.Kodera, A.Nakao, K.Yamamura, T.Gewen, W.Zhiwen, Y.Hotta, S.Yamada, T.Fujii, S.Fukuda et al. Phase I dose-escalation clinical trial of HF10 oncolytic herpes virus in 17 Japanese patients with advanced cancer. Hepatogastroenterology 2014; 61:599-605; PMID:26176043
201. D.Dingli, K.W.Peng, M.E.Harvey, P.R.Greipp, M.K.O'Connor, R.Cattaneo, J.C.Morris, S.J.Russell. Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter. Blood 2004; 103:1641-6; PMID:14604966; http://dx.doi.org/10.1182/blood-2003-07-2233
202. J.F.Fonteneau, J.B.Guillerme, F.Tangy, M.Gregoire. Attenuated measles virus used as an oncolytic virus activates myeloid and plasmacytoid dendritic cells. Oncoimmunology 2013; 2:e24212; PMID:23762802; http://dx.doi.org/10.4161/onci.24212
203. S.J.Russell, M.J.Federspiel, K.W.Peng, C.Tong, D.Dingli, W.G.Morice, V.Lowe, M.K.O'Connor, R.A.Kyle, N.Leung et al. Remission of disseminated cancer after systemic oncolytic virotherapy. Mayo Clin Proc 2014; 89:926-33; PMID:24835528; http://dx.doi.org/10.1016/j.mayocp.2014.04.003
204. T.Umeoka, T.Kawashima, S.Kagawa, F.Teraishi, M.Taki, M.Nishizaki, S.Kyo, K.Nagai, Y.Urata, N.Tanaka et al. Visualization of intrathoracically disseminated solid tumors in mice with optical imaging by telomerase-specific amplification of a transferred green fluorescent protein gene. Cancer Res 2004; 64:6259-65; PMID:15342413; http://dx.doi.org/10.1158/0008-5472.CAN-04-1335
205. S.Tanabe, H.Tazawa, S.Kagawa, K.Noma, K.Takehara, T.Koujima, H.Kashima, T.Kato, S.Kuroda, S.Kikuchi et al. Phase I/II trial of endoscopic intratumoral administration of OBP-301, a novel telomerase-specific oncolytic virus, with radiation in elderly esophageal cancer patients. Cancer Res 2015; 75:Abstract CT213; http://dx.doi.org/10.1158/1538-7445.AM2015-CT123
206. S.H.Thorne. Immunotherapeutic potential of oncolytic vaccinia virus. Front Oncol 2014; 4:155; PMID:24987615; http://dx.doi.org/10.3389/fonc.2014.00155
207. H.J.Zeh, S.Downs-Canner, J.A.McCart, Z.S.Guo, U.N.Rao, L.Ramalingam, S.H.Thorne, H.L.Jones, P.Kalinski, E.Wieckowski et al. First-in-man study of western reserve strain oncolytic vaccinia virus: safety, systemic spread, and antitumor activity. Mol Ther 2015; 23:202-14; PMID:25292189; http://dx.doi.org/10.1038/mt.2014.194
208. L.K.Spary, J.Salimu, J.P.Webber, A.Clayton, M.D.Mason, Z.Tabi. Tumor stroma-derived factors skew monocyte to dendritic cell differentiation toward a suppressive CD14 PD-L1 phenotype in prostate cancer. Oncoimmunology 2014; 3:e955331; PMID:25941611; http://dx.doi.org/10.4161/21624011.2014.955331
209. P.Mesange, V.Poindessous, M.Sabbah, A.E.Escargueil, A.de Gramont, A.K.Larsen. Intrinsic bevacizumab resistance is associated with prolonged activation of autocrine VEGF signaling and hypoxia tolerance in colorectal cancer cells and can be overcome by nintedanib, a small molecule angiokinase inhibitor. Oncotarget 2014; 5:4709-21; PMID:25015210; http://dx.doi.org/10.18632/oncotarget.1671
210. L.Zitvogel, L.Galluzzi, O.Kepp, M.J.Smyth, G.Kroemer. Type I interferons in anticancer immunity. Nat Rev Immunol 2015; 15:405-14; PMID:26027717; http://dx.doi.org/10.1038/nri3845
211. R.Arulanandam, C.Batenchuk, F.A.Angarita, K.Ottolino-Perry, S.Cousineau, A.Mottashed, E.Burgess, T.J.Falls, N.De Silva, J.Tsang et al. VEGF-Mediated Induction of PRD1-BF1/Blimp1 Expression Sensitizes Tumor Vasculature to Oncolytic Virus Infection. Cancer Cell 2015; 28:210-24; PMID:26212250; http://dx.doi.org/10.1016/j.ccell.2015.06.009
212. B.R.Kim, K.Yoon, H.J.Byun, S.H.Seo, S.H.Lee, S.B.Rho. The anti-tumor activator sMEK1 and paclitaxel additively decrease expression of HIF-1alpha and VEGF via mTORC1-S6K/4E-BP-dependent signaling pathways. Oncotarget 2014; 5:6540-51; PMID:25153728; http://dx.doi.org/10.18632/oncotarget.2119
213. F.Lovat, H.Ishii, M.Schiappacassi, M.Fassan, M.Barbareschi, E.Galligioni, P.Gasparini, G.Baldassarre, C.M.Croce, A.Vecchione. LZTS1 downregulation confers paclitaxel resistance and is associated with worse prognosis in breast cancer. Oncotarget 2014; 5:970-7; PMID:24448468; http://dx.doi.org/10.18632/oncotarget.1630
214. R.Arulanandam, C.Batenchuk, O.Varette, C.Zakaria, V.Garcia, N.E.Forbes, C.Davis, R.Krishnan, R.Karmacharya, J.Cox et al. Microtubule disruption synergizes with oncolytic virotherapy by inhibiting interferon translation and potentiating bystander killing. Nat Commun 2015; 6:6410; PMID:25817275; http://dx.doi.org/10.1038/ncomms7410
215. F.Aranda, E.Vacchelli, F.Obrist, A.Eggermont, J.Galon, W.Herve Fridman, I.Cremer, E.Tartour, L.Zitvogel, G.Kroemer et al. Trial Watch: Adoptive cell transfer for anticancer immunotherapy. Oncoimmunology 2014; 3:e28344; PMID:25050207; http://dx.doi.org/10.4161/onci.28344
216. E.Vacchelli, A.Eggermont, W.H.Fridman, J.Galon, E.Tartour, L.Zitvogel, G.Kroemer, L.Galluzzi. Trial Watch: Adoptive cell transfer for anticancer immunotherapy. Oncoimmunology 2013; 2:e24238; PMID:23762803; http://dx.doi.org/10.4161/onci.24238
217. N.Nishio, I.Diaconu, H.Liu, V.Cerullo, I.Caruana, V.Hoyos, L.Bouchier-Hayes, B.Savoldo, G.Dotti. Armed oncolytic virus enhances immune functions of chimeric antigen receptor-modified T cells in solid tumors. Cancer Res 2014; 74:5195-205; PMID:25060519; http://dx.doi.org/10.1158/0008-5472.CAN-14-0697
218. G.Kroemer, L.Galluzzi, O.Kepp, L.Zitvogel. Immunogenic cell death in cancer therapy. Annu Rev Immunol 2013; 31:51-72; PMID:23157435; http://dx.doi.org/10.1146/annurev-immunol-032712-100008
219. E.Vacchelli, F.Aranda, A.Eggermont, J.Galon, C.Sautes-Fridman, I.Cremer, L.Zitvogel, G.Kroemer, L.Galluzzi. Trial Watch: Chemotherapy with immunogenic cell death inducers. Oncoimmunology 2014; 3:e27878; PMID:24800173; http://dx.doi.org/10.4161/onci.27878
220. M.A.Hamouda, N.Belhacene, A.Puissant, P.Colosetti, G.Robert, A.Jacquel, B.Mari, P.Auberger, F.Luciano. The small heat shock protein B8 (HSPB8) confers resistance to bortezomib by promoting autophagic removal of misfolded proteins in multiple myeloma cells. Oncotarget 2014; 5:6252-66; PMID:25051369; http://dx.doi.org/10.18632/oncotarget.2193
221. K.S.Siveen, N.Mustafa, F.Li, R.Kannaiyan, K.S.Ahn, A.P.Kumar, W.J.Chng, G.Sethi. Thymoquinone overcomes chemoresistance and enhances the anticancer effects of bortezomib through abrogation of NF-kappaB regulated gene products in multiple myeloma xenograft mouse model. Oncotarget 2014; 5:634-48; PMID:24504138; http://dx.doi.org/10.18632/oncotarget.1596
222. E.Vacchelli, L.Senovilla, A.Eggermont, W.H.Fridman, J.Galon, L.Zitvogel, G.Kroemer, L.Galluzzi. Trial watch: Chemotherapy with immunogenic cell death inducers. Oncoimmunology 2013; 2:e23510; PMID:23687621; http://dx.doi.org/10.4161/onci.23510
223. J.Y.Yoo, B.S.Hurwitz, C.Bolyard, J.G.Yu, J.Zhang, K.Selvendiran, K.S.Rath, S.He, Z.Bailey, D.Eaves et al. Bortezomib-induced unfolded protein response increases oncolytic HSV-1 replication resulting in synergistic antitumor effects. Clin Cancer Res 2014; 20:3787-98; PMID:24815720; http://dx.doi.org/10.1158/1078-0432.CCR-14-0553
224. E.Vacchelli, A.Eggermont, J.Galon, C.Sautes-Fridman, L.Zitvogel, G.Kroemer, L.Galluzzi. Trial watch: Monoclonal antibodies in cancer therapy. Oncoimmunology 2013; 2:e22789; PMID:23482847; http://dx.doi.org/10.4161/onci.22789
225. E.Vacchelli, F.Aranda, A.Eggermont, J.Galon, C.Sautes-Fridman, L.Zitvogel, G.Kroemer, L.Galluzzi. Trial Watch: Tumor-targeting monoclonal antibodies in cancer therapy. Oncoimmunology 2014; 3:e27048; PMID:24605265; http://dx.doi.org/10.4161/onci.27048
226. C.Parrish, G.B.Scott, G.Migneco, K.J.Scott, L.P.Steele, E.Ilett, E.J.West, K.Hall, P.J.Selby, D.Buchanan et al. Oncolytic reovirus enhances rituximab-mediated antibody-dependent cellular cytotoxicity against chronic lymphocytic leukaemia. Leukemia 2015; 29:1799-810; PMID:25814029; http://dx.doi.org/10.1038/leu.2015.88
227. S.S.Ho, S.Gasser. NKG2D ligands link oncogenic RAS to innate immunity. Oncoimmunology 2013; 2:e22244; PMID:23482418; http://dx.doi.org/10.4161/onci.22244
228. Y.Komatsu, S.L.Christian, N.Ho, T.Pongnopparat, M.Licursi, K.Hirasawa. Oncogenic Ras inhibits IRF1 to promote viral oncolysis. Oncogene 2015; 34:3985-93; PMID:25347735; http://dx.doi.org/10.1038/onc.2014.331
229. C.S.Ilkow, M.Marguerie, C.Batenchuk, J.Mayer, D.Ben Neriah, S.Cousineau, T.Falls, V.A.Jennings, M.Boileau, D.Bellamy et al. Reciprocal cellular cross-talk within the tumor microenvironment promotes oncolytic virus activity. Nat Med 2015; 21:530-6; PMID:25894825; http://dx.doi.org/10.1038/nm.3848
230. M.Gayral, H.Lulka, N.Hanoun, C.Biollay, J.Selves, A.Vignolle-Vidoni, H.Berthommé, P.Trempat, A.L.Epstein, L.Buscail et al. Targeted oncolytic herpes simplex virus type 1 eradicates experimental pancreatic tumors. Hum Gene Ther 2015; 26:104-13; PMID:25423447; http://dx.doi.org/10.1089/hum.2014.072
231. S.N.Byrne, S.N.Sarchio. AMD3100 protects from UV-induced skin cancer. Oncoimmunology 2014; 3:e27562; PMID:24744978; http://dx.doi.org/10.4161/onci.27562
232. T.J.Waldron, J.G.Quatromoni, T.A.Karakasheva, S.Singhal, A.K.Rustgi. Myeloid derived suppressor cells: Targets for therapy. Oncoimmunology 2013; 2:e24117; PMID:23734336; http://dx.doi.org/10.4161/onci.24117
233. M.Gil, M.P.Komorowski, M.Seshadri, H.Rokita, A.J.McGray, M.Opyrchal, K.O.Odunsi, D.Kozbor. CXCL12/CXCR4 blockade by oncolytic virotherapy inhibits ovarian cancer growth by decreasing immunosuppression and targeting cancer-initiating cells. J Immunol 2014; 193:5327-37; PMID:25320277; http://dx.doi.org/10.4049/jimmunol.1400201
234. A.Martens, H.Zelba, C.Garbe, G.Pawelec, B.Weide. Monocytic myeloid-derived suppressor cells in advanced melanoma patients: Indirect impact on prognosis through inhibition of tumor-specific T-cell responses? Oncoimmunology 2014; 3:e27845; PMID:24800171; http://dx.doi.org/10.4161/onci.27845
235. D.R.Clements, A.M.Sterea, Y.Kim, E.Helson, C.A.Dean, A.Nunokawa, K.M.Coyle, T.Sharif, P.Marcato, S.A.Gujar et al. Newly recruited CD11b+, GR-1+, Ly6C(high) myeloid cells augment tumor-associated immunosuppression immediately following the therapeutic administration of oncolytic reovirus. J Immunol 2015; 194:4397-412; PMID:25825443; http://dx.doi.org/10.4049/jimmunol.1402132
236. J.C.Paglino, W.Andres, A.N.van den Pol. Autonomous parvoviruses neither stimulate nor are inhibited by the type I interferon response in human normal or cancer cells. J Virol 2014; 88:4932-42; PMID:24554651; http://dx.doi.org/10.1128/JVI.03508-13
237. A.Zloza, D.W.Kim, S.Kim-Schulze, M.C.Jagoda, V.Monsurro, F.M.Marincola, H.L.Kaufman. Immunoglobulin-like transcript 2 (ILT2) is a biomarker of therapeutic response to oncolytic immunotherapy with vaccinia viruses. J Immunother Cancer 2014; 2:1; PMID:24829758; http://dx.doi.org/10.1186/2051-1426-2-1
238. I.Adkins, J.Fucikova, A.D.Garg, P.Agostinis, R.Spisek. Physical modalities inducing immunogenic tumor cell death for cancer immunotherapy. Oncoimmunology 2014; 3:e968434; PMID:25964865; http://dx.doi.org/10.4161/21624011.2014.968434
239. F.Aranda, E.Vacchelli, F.Obrist, A.Eggermont, J.Galon, C.Sautes-Fridman, I.Cremer, J.Henrik Ter Meulen, L.Zitvogel, G.Kroemer et al. Trial Watch: Toll-like receptor agonists in oncological indications. Oncoimmunology 2014; 3:e29179; PMID:25083332; http://dx.doi.org/10.4161/onci.29179
240. C.Brenner, L.Galluzzi, O.Kepp, G.Kroemer. Decoding cell death signals in liver inflammation. J Hepatol 2013; 59:583-94; PMID:23567086; http://dx.doi.org/10.1016/j.jhep.2013.03.033
241. E.Vacchelli, A.Eggermont, C.Sautes-Fridman, J.Galon, L.Zitvogel, G.Kroemer, L.Galluzzi. Trial Watch: Toll-like receptor agonists for cancer therapy. Oncoimmunology 2013; 2:e25238; PMID:24083080; http://dx.doi.org/10.4161/onci.25238
242. I.Liikanen, A.Koski, M.Merisalo-Soikkeli, O.Hemminki, M.Oksanen, K.Kairemo, T.Joensuu, A.Kanerva, A.Hemminki. Serum HMGB1 is a predictive and prognostic biomarker for oncolytic immunotherapy. Oncoimmunology 2015; 4:e989771; PMID:25949903; http://dx.doi.org/10.4161/2162402X.2014.989771
243. D.Kuruppu, A.L.Brownell, K.Shah, U.Mahmood, K.K.Tanabe. Molecular imaging with bioluminescence and PET reveals viral oncolysis kinetics and tumor viability. Cancer Res 2014; 74:4111-21; PMID:24876106; http://dx.doi.org/10.1158/0008-5472.CAN-13-3472
244. J.Crouse, U.Kalinke, A.Oxenius. Regulation of antiviral T cell responses by type I interferons. Nat Rev Immunol 2015; 15:231-42; PMID:25790790; http://dx.doi.org/10.1038/nri3806
245. F.McNab, K.Mayer-Barber, A.Sher, A.Wack, A.O'Garra. Type I interferons in infectious disease. Nat Rev Immunol 2015; 15:87-103; PMID:25614319; http://dx.doi.org/10.1038/nri3787
246. A.Sistigu, T.Yamazaki, E.Vacchelli, K.Chaba, D.P.Enot, J.Adam, I.Vitale, A.Goubar, E.E.Baracco, C.Remédios et al. Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. Nat Med 2014; 20:1301-9; PMID:25344738; http://dx.doi.org/10.1038/nm.3708
247. J.Pol, N.Bloy, F.Obrist, A.Eggermont, J.Galon, I.Cremer, P.Erbs, J.M.Limacher, X.Preville, L.Zitvogel et al. Trial Watch: Oncolytic viruses for cancer therapy. Oncoimmunology 2014; 3:e28694; PMID:25097804; http://dx.doi.org/10.4161/onci.28694
248. N.Ramesh, Y.Ge, D.L.Ennist, M.Zhu, M.Mina, S.Ganesh, P.S.Reddy, D.C.Yu. CG0070, a conditionally replicating granulocyte macrophage colony-stimulating factor–armed oncolytic adenovirus for the treatment of bladder cancer. Clin Cancer Res 2006; 12:305-13; PMID:16397056; http://dx.doi.org/10.1158/1078-0432.CCR-05-1059
249. T.T.Huang, J.Hlavaty, D.Ostertag, F.L.Espinoza, B.Martin, H.Petznek, M.Rodriguez-Aguirre, C.E.Ibañez, N.Kasahara, W.Gunzburg et al. Toca 511 gene transfer and 5-fluorocytosine in combination with temozolomide demonstrates synergistic therapeutic efficacy in a temozolomide-sensitive glioblastoma model. Cancer Gene Ther 2013; 20:544-51; PMID:23969884; http://dx.doi.org/10.1038/cgt.2013.51
250. O.D.Perez, C.R.Logg, K.Hiraoka, O.Diago, R.Burnett, A.Inagaki, D.Jolson, K.Amundson, T.Buckley, D.Lohse et al. Design and selection of Toca 511 for clinical use: modified retroviral replicating vector with improved stability and gene expression. Mol Ther 2012; 20:1689-98; PMID:22547150; http://dx.doi.org/10.1038/mt.2012.83
251. D.Ostertag, K.K.Amundson, F.Lopez Espinoza, B.Martin, T.Buckley, A.P.Galvao da Silva, A.H.Lin, D.T.Valenta, O.D.Perez, C.E.Ibañez et al. Brain tumor eradication and prolonged survival from intratumoral conversion of 5-fluorocytosine to 5-fluorouracil using a nonlytic retroviral replicating vector. Neuro Oncol 2012; 14:145-59; PMID:22070930; http://dx.doi.org/10.1093/neuonc/nor199
252. F.Ghiringhelli, M.Bruchard, L.Apetoh. Immune effects of 5-fluorouracil: Ambivalence matters. Oncoimmunology 2013; 2:e23139; PMID:23802066; http://dx.doi.org/10.4161/onci.23139
253. M.M.Alonso, C.Gomez-Manzano, B.N.Bekele, W.K.Yung, J.Fueyo. Adenovirus-based strategies overcome temozolomide resistance by silencing the O6-methylguanine-DNA methyltransferase promoter. Cancer Res 2007; 67:11499-504; PMID:18089777; http://dx.doi.org/10.1158/0008-5472.CAN-07-5312
254. M.M.Alonso, H.Jiang, T.Yokoyama, J.Xu, N.B.Bekele, F.F.Lang, S.Kondo, C.Gomez-Manzano, J.Fueyo. Delta-24-RGD in combination with RAD001 induces enhanced anti-glioma effect via autophagic cell death. Mol Ther 2008; 16:487-93; PMID:18253154; http://dx.doi.org/10.1038/sj.mt.6300400
255. A.Kleijn, J.Kloezeman, E.Treffers-Westerlaken, G.Fulci, S.Leenstra, C.Dirven, R.Debets, M.Lamfers. The therapeutic efficacy of the oncolytic virus Delta24-RGD in a murine glioma model depends primarily on antitumor immunity. Oncoimmunology 2014; 3:e955697; PMID:25941622; http://dx.doi.org/10.4161/21624011.2014.955697
256. V.G.Brichard, Q.Godechal. MAGE-A3-specific anticancer immunotherapy in the clinical practice. Oncoimmunology 2013; 2:e25995; PMID:24244898; http://dx.doi.org/10.4161/onci.25995
257. N.Schmidt, T.Flecken, R.Thimme. Tumor-associated antigen specific CD8 T cells in hepatocellular carcinoma - a promising target for immunotherapy. Oncoimmunology 2014; 3:e954919; PMID:25941604; http://dx.doi.org/10.4161/21624011.2014.954919
258. E.Vacchelli, A.Eggermont, W.H.Fridman, J.Galon, L.Zitvogel, G.Kroemer, L.Galluzzi. Trial Watch: Immunostimulatory cytokines. Oncoimmunology 2013; 2:e24850; PMID:24073369; http://dx.doi.org/10.4161/onci.24850
259. E.Vacchelli, F.Aranda, F.Obrist, A.Eggermont, J.Galon, I.Cremer, L.Zitvogel, G.Kroemer, L.Galluzzi. Trial watch: Immunostimulatory cytokines in cancer therapy. Oncoimmunology 2014; 3:e29030; PMID:25083328; http://dx.doi.org/10.4161/onci.29030
260. R.H.I.Andtbacka, M.Chastain, A.Li, M.Shilkrut, M.I.Ross. Phase 2, multicenter, randomized, open-label trial assessing efficacy and safety of talimogene laherparepvec (T-VEC) neoadjuvant treatment (tx) plus surgery vs surgery for resectable stage IIIB/C and IVM1a melanoma (MEL). ASCO Meeting Abstracts 2015; 33:TPS9094
261. J.M.Taube. Unleashing the immune system: PD-1 and PD-Ls in the pre-treatment tumor microenvironment and correlation with response to PD-1/PD-L1 blockade. Oncoimmunology 2014; 3:e963413; PMID:25914862; http://dx.doi.org/10.4161/21624011.2014.963413
262. S.Munir, G.H.Andersen, I.M.Svane, M.H.Andersen. The immune checkpoint regulator PD-L1 is a specific target for naturally occurring CD4 T cells. Oncoimmunology 2013; 2:e23991; PMID:23734334; http://dx.doi.org/10.4161/onci.23991
263. P.Kharaziha, H.De Raeve, C.Fristedt, Q.Li, A.Gruber, P.Johnsson, G.Kokaraki, M.Panzar, E.Laane, A.Osterborg et al. Sorafenib has potent antitumor activity against multiple myeloma in vitro, ex vivo, and in vivo in the 5T33MM mouse model. Cancer Res 2012; 72:5348-62; PMID:22952216; http://dx.doi.org/10.1158/0008-5472.CAN-12-0658
264. P.Kharaziha, P.Rodriguez, Q.Li, H.Rundqvist, A.C.Bjorklund, M.Augsten, A.Ullén, L.Egevad, P.Wiklund, S.Nilsson et al. Targeting of distinct signaling cascades and cancer-associated fibroblasts define the efficacy of Sorafenib against prostate cancer cells. Cell Death Dis 2012; 3:e262; PMID:22278289; http://dx.doi.org/10.1038/cddis.2012.1
265. C.J.Breitbach, A.Moon, J.Burke, T.H.Hwang, D.H.Kirn. A phase 2, open-label, randomized study of pexa-vec (JX-594) administered by intratumoral injection in patients with unresectable primary hepatocellular Carcinoma. Methods Mol Biol 2015; 1317:343-57; PMID:26072416; http://dx.doi.org/10.1007/978-1-4939-2727-2_19
266. E.Vacchelli, A.Eggermont, C.Sautes-Fridman, J.Galon, L.Zitvogel, G.Kroemer, L.Galluzzi. Trial watch: Oncolytic viruses for cancer therapy. Oncoimmunology 2013; 2:e24612; PMID:23894720; http://dx.doi.org/10.4161/onci.24612
267. I.A.McNeish, A.Michael, C.Twelves, R.Glasspool, M.A.Ajaz, R.Morrison, Q.Xeniou, R.Brown, K.Fisher, C.Blanc. A phase I/II study of Enadenotucirev, an oncolytic Ad11/Ad3 chimeric group B adenovirus, administered intraperitoneally (IP): Dose finding and proof of concept in platinum-resistant epithelial ovarian cancer. ASCO Meeting Abstracts 2015; 33:TPS5611
268. R.L.Ferris, N.D.Gross, J.J.Nemunaitis, R.H.I.Andtbacka, A.Argiris, J.Ohr, J.T.Vetto, N.N.Senzer, C.Bedell, R.S.Ungerleider et al. Phase I trial of intratumoral therapy using HF10, an oncolytic HSV-1, demonstrates safety in HSV+/HSV- patients with refractory and superficial cancers. ASCO Meeting Abstracts 2014; 32:6082
269. R.H.Vonderheide, J.M.Burg, R.Mick, J.A.Trosko, D.Li, M.N.Shaik, A.W.Tolcher, O.Hamid. Phase I study of the CD40 agonist antibody CP-870,893 combined with carboplatin and paclitaxel in patients with advanced solid tumors. Oncoimmunology 2013; 2:e23033; PMID:23483678; http://dx.doi.org/10.4161/onci.23033
270. L.Galluzzi, L.Senovilla, I.Vitale, J.Michels, I.Martins, O.Kepp, M.Castedo, G.Kroemer. Molecular mechanisms of cisplatin resistance. Oncogene 2012; 31:1869-83; PMID:21892204; http://dx.doi.org/10.1038/onc.2011.384
271. S.A.Gujar, D.Clements, P.W.Lee. Two is better than one: Complementing oncolytic virotherapy with gemcitabine to potentiate antitumor immune responses. Oncoimmunology 2014; 3:e27622; PMID:24804161; http://dx.doi.org/10.4161/onci.27622